NOT FOR DISTRIBUTION
Header cover image

Market Cap

CHF3.1b

Last Updated

2021/05/15 18:09 UTC

Data Sources

Company Financials +

Executive Summary

Zur Rose Group AG operates an e-commerce pharmacy and a wholesale business for medical and pharmaceutical products under the Zur Rose and DocMorris brands in Germany, Switzerland, and rest of Europe. More Details


Snowflake Analysis

High growth potential with mediocre balance sheet.


Similar Companies

Share Price & News

How has Zur Rose Group's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ROSE is more volatile than 90% of Swiss stocks over the past 3 months, typically moving +/- 9% a week.

Volatility Over Time: ROSE's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of Swiss stocks.


Market Performance


7 Day Return

7.6%

ROSE

1.6%

CH Consumer Retailing

-0.8%

CH Market


1 Year Return

95.1%

ROSE

10.7%

CH Consumer Retailing

17.7%

CH Market

Return vs Industry: ROSE exceeded the Swiss Consumer Retailing industry which returned 10.8% over the past year.

Return vs Market: ROSE exceeded the Swiss Market which returned 17.7% over the past year.


Shareholder returns

ROSEIndustryMarket
7 Day7.6%1.6%-0.8%
30 Day-11.8%3.6%-1.8%
90 Day-36.1%-0.6%2.4%
1 Year95.1%95.1%20.1%10.7%21.1%17.7%
3 Year162.9%162.9%20.1%3.8%30.1%15.3%
5 Yearn/a24.6%2.1%59.6%30.5%

Long-Term Price Volatility Vs. Market

How volatile is Zur Rose Group's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Zur Rose Group undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ROSE (CHF325) is trading below our estimate of fair value (CHF1384.14)

Significantly Below Fair Value: ROSE is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ROSE is unprofitable, so we can't compare its PE Ratio to the European Consumer Retailing industry average.

PE vs Market: ROSE is unprofitable, so we can't compare its PE Ratio to the Swiss market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ROSE's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ROSE is overvalued based on its PB Ratio (5.9x) compared to the XE Consumer Retailing industry average (2x).


Future Growth

How is Zur Rose Group forecast to perform in the next 1 to 3 years based on estimates from 9 analysts?

45.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ROSE is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (-0.3%).

Earnings vs Market: ROSE is forecast to become profitable over the next 3 years, which is considered above average market growth.

High Growth Earnings: ROSE's is expected to become profitable in the next 3 years.

Revenue vs Market: ROSE's revenue (26.2% per year) is forecast to grow faster than the Swiss market (4.5% per year).

High Growth Revenue: ROSE's revenue (26.2% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: ROSE is forecast to be unprofitable in 3 years.


Past Performance

How has Zur Rose Group performed over the past 5 years?

-50.3%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ROSE is currently unprofitable.

Growing Profit Margin: ROSE is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ROSE is unprofitable, and losses have increased over the past 5 years at a rate of 50.3% per year.

Accelerating Growth: Unable to compare ROSE's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ROSE is unprofitable, making it difficult to compare its past year earnings growth to the Consumer Retailing industry (15.6%).


Return on Equity

High ROE: ROSE has a negative Return on Equity (-25.51%), as it is currently unprofitable.


Financial Health

How is Zur Rose Group's financial position?


Financial Position Analysis

Short Term Liabilities: ROSE's short term assets (CHF539.3M) exceed its short term liabilities (CHF156.7M).

Long Term Liabilities: ROSE's short term assets (CHF539.3M) do not cover its long term liabilities (CHF590.1M).


Debt to Equity History and Analysis

Debt Level: ROSE's debt to equity ratio (91%) is considered high.

Reducing Debt: ROSE's debt to equity ratio has increased from 79.6% to 91% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ROSE has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: ROSE has sufficient cash runway for 3 years if free cash flow continues to reduce at historical rates of 35% each year.


Dividend

What is Zur Rose Group current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ROSE's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ROSE's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ROSE's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ROSE's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: ROSE is not paying a notable dividend for the Swiss market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ROSE's dividend in 3 years as they are not forecast to pay a notable one for the Swiss market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Walter Oberhänsli (62 yo)

16.33yrs

Tenure

CHF1,337,000

Compensation

Mr. Walter Oberhänsli serves as the Chief Executive Officer at Zur Rose Group AG since 2005. Mr. Oberhänsli served as Member of the Executive Board. He served as Chairman of the Board at Zur Rose Group AG ...


CEO Compensation Analysis

Compensation vs Market: Walter's total compensation ($USD1.48M) is about average for companies of similar size in the Swiss market ($USD1.48M).

Compensation vs Earnings: Walter's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: ROSE's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

Experienced Board: ROSE's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Zur Rose Group AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Zur Rose Group AG
  • Ticker: ROSE
  • Exchange: SWX
  • Founded: 1993
  • Industry: Drug Retail
  • Sector: Consumer Retailing
  • Market Cap: CHF3.111b
  • Shares outstanding: 9.57m
  • Website: https://www.zurrosegroup.com

Number of Employees


Location

  • Zur Rose Group AG
  • WalzmUehlestrasse 60
  • Frauenfeld
  • Thurgau
  • 8500
  • Switzerland

Listings


Biography

Zur Rose Group AG operates an e-commerce pharmacy and a wholesale business for medical and pharmaceutical products under the Zur Rose and DocMorris brands in Germany, Switzerland, and rest of Europe. It of...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/05/15 18:09
End of Day Share Price2021/05/14 00:00
Earnings2020/12/31
Annual Earnings2020/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.